Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Immunology
Published in: BMC Immunology 1/2019

Open Access 01-12-2019 | Septicemia | Research article

Soluble CD14 subtype (sCD14-ST) as biomarker in neonatal early-onset sepsis and late-onset sepsis: a systematic review and meta-analysis

Authors: Iris van Maldeghem, Charlotte M. Nusman, Douwe H. Visser

Published in: BMC Immunology | Issue 1/2019

Login to get access

Abstract

Background

Early diagnosis of bacterial sepsis in neonates is hampered by non-specific symptoms and the lack of rapid responding laboratory measures. The biomarker soluble CD14 subtype (sCD14-ST) seems promising in the diagnostic process of neonatal sepsis. In order to evaluate the differences in diagnostic accuracy of sCD14-ST between early onset sepsis (EOS) and late onset sepsis (LOS) we assessed this systematic review and meta-analysis.

Results

Twelve articles were included in the systematic review and 10 in the meta-analysis. There was a high risk of bias on patient selection, index test and/or flow and timing. The overall quality of the included studies was moderate.
At sepsis onset a consequently higher level of sCD14-ST was found in septic neonates compared to healthy controls with significant higher levels in LOS compared to EOS. In the first 24 h after sepsis onset a significant increase in pooled means of plasma sCD14-ST levels was seen in EOS (t(71.6) = 7.3, p < .0001) while this was not seen in LOS or healthy controls. Optimal cut-off values ranged from 305 to 672 ng/l for EOS cases versus healthy controls. The pooled sensitivity was 81% (95%CI: 0.76–0.85), the pooled specificity was 86% (0.81–0.89) with an AUC of 0.9412 (SE 0.1178). In LOS optimal cut-off values ranged from 801 to 885 ng/l with a pooled sensitivity of 81% (0.74–0.86) and a pooled specificity of 100% (0.98–1.00). An AUC and SROC was not estimable in LOS because of the low number of studies.

Conclusions

sCD14-ST is a promising and rapid-responding diagnostic biomarker for EOS and LOS. The difference in pooled means between EOS and LOS underlines the importance to consider EOS and LOS as two different disease entities, requiring separate analysis in original articles and systematic reviews.
Appendix
Available only for authorised users
Literature
1.
Camacho-Gonzalez A, Spearman PW, Stoll BJ. Neonatal infectious diseases: evaluation of neonatal sepsis. Pediatr Clin N Am. 2013;60(2):367–89.CrossRef
2.
Heron M. Deaths: leading causes for 2013. Natl Vital Stat Rep. 2016;65(2):1–95.PubMed
3.
Boghossian NS, Page GP, Bell EF, et al. Late-onset sepsis in very low birth weight infants from singleton and multiple-gestation births. J Pediatr. 2013;162(6):1120–4.CrossRef
4.
Ballot DE, Chirwa T, Ramdin T, et al. Comparison of morbidity and mortality of very low birth weight infants in a central Hospital in Johannesburg between 2006/2007 and 2013. BMC Pediatr. 2015;15(1):20.
5.
Mussap M, Noto A, Fravega M, Fanos V. Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: new clinical and analytical perspectives for two old biomarkers. J Matern Fetal Neonatal Med. 2011;24(2):12–4.CrossRef
6.
Delanghe JR, Speeckaert MM. Translational research and biomarkers in neonatal sepsis. Clin Chim Acta. 2015;451:46–64.CrossRef
7.
Chenevier-Gobeaux C, Bardet V, Poupet H, Poyart H, Borderie D, Claessens YE, et al. Presepsin (sCD14-ST) secretion and kinetics by peripheral blood mononuclear cells and monocytic THP-1 cell line. Ann Biol Clin (Paris). 2016;74(1):93–7.
8.
Bellos I, Fitrou G, Pergialiotis V, Thomakos N, Perrea DN, Daskalakis G. The diagnostic accuracy of presepsin in neonatal sepsis: a meta-analysis. Eur J Pediatr. 2018;177(5):625–32.CrossRef
9.
Montaldo P, Rosso R, Santantonio A, Chello G, Giliberti P. Presepsin for the detection of early-onset sepsis in preterm newborns. Pediatr Res. 2016;81(2):329–34.CrossRef
10.
Poggi C, Bianconi T, Gozzini E, Generoso M, Dani C. Presepsin for the detection of late-onset sepsis in preterm newborns. Pediatrics. 2015;135(1):68–75.CrossRef
11.
Ozdemir AA, Elgormus Y. Diagnostic value of Presepsin in detection of early-onset neonatal Sepsis. Am J Perinatol. 2017;34(06):550–6.CrossRef
12.
Topcuoglu S, Arslanbuga C, Gursoy T, et al. Role of presepsin in the diagnosis of late-onset neonatal sepsis in preterm infants. J Matern Fetal Neonatal Med. 2016;29(11):1834–9.PubMed
13.
Xiao T, Chen LP, Zhang LH, et al. The clinical significance of sCD14-ST for blood biomarker in neonatal hematosepsis: a diagnostic accuracy study. Medicine (Baltimore). 2017;96(18):e6823.CrossRef
14.
Liberati A, Altman D, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.CrossRef
15.
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.
16.
Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–36.CrossRef
17.
Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006;6(31):31.
18.
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
19.
Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.
20.
21.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.CrossRef
22.
Macaskill P, Gatsonis C, Deeks JJ, Harbord RM, Takwoingi Y. Chapter 10: Analysing and Presenting Results. In: Deeks JJ, Bossuyt PM, Gatsonis C (editors), Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0. The Cochrane Collaboration, 2010. Available from: http://​srdta.​cochrane.​org/​.
23.
Van Enst WA, Ochodo E, Scholten RJPM, Hooft L, Leeflang MM. Investigation of publication bias in meta-analyses of diagnostic test accuracy: a meta-epidemiological study. BMC Med Res Methodol. 2014;14(1):70.
24.
Tabl HA, Abed NT. Diagnostic value of presepsin in neonatal sepsis. Egypt J Immunol. 2016;23(2):29–37.PubMed
25.
Sabry JH, Elfeky OA, Elsadek AE, Eldaly AA. Presepsin as an early reliable diagnostic and prognostic marker of neonatal sepsis. Int J Adv Res. 2016;4(6):1538–49.CrossRef
26.
Mostafa RM, Kholouss SM, MZakaria N, Hafiz TR, Abdelaziz DM. Detection of presepsin and surface CD14 as a biomarker for early diagnosis of neonatal sepsis. J Am Sci. 2015;11(10):104–116.
27.
Osman AS, Awadallah MG, Tabl HAEM, Abed NT, Goudah ESS. Presepsin as a novel diagnostic marker in neonatal septicemia. Egypt J Med Microbiol. 2015;24(3):21–6.CrossRef
28.
Ta M, Khalaf FA, El Hendawy G, Kotb SE, Ali AM, El Sharnoby A. Soluble CD14-subtype (Prespsin) and Hepcidin as diagnostic and prognostic markers in early onset neonatal sepsis. Egypt J Med Microbiol. 2015;24(3):45–52.CrossRef
29.
Mussap M, Puxeddu E, Burrai P, et al. Soluble CD14 subtype (sCD14-ST) presepsin in critically ill preterm newborns: preliminary reference ranges. J Matern Fetal Neonatal Med. 2012;25(sup5):51–3.CrossRef
30.
Mussap M, Puxeddu E, Puddu M, et al. Soluble CD14 subtype (sCD14-ST) presepsin in premature and full term critically ill newborns with sepsis and SIRS. Clin Chim Acta. 2015;451:65–70.CrossRef
31.
Pugni L, Pietrasanta C, Milani S, et al. Presepsin (soluble CD14 subtype): reference ranges of a new sepsis marker in term and preterm neonates. PLoS One. 2015;10:e0146020.CrossRef
32.
Miyosawa Y, Akazawa Y, Kamiya M, et al. Presepsin as a predictor of positive blood culture in suspected neonatal sepsis. Pediatr Int. 2018;60(2):157–161.CrossRef
33.
Iskandar A, Arthamin MZ, Indriana K, et al. Comparison between presepsin and procalcitonin in early diagnosis of neonatal sepsis. J Matern Fetal Neonatal Med. 2018;1–6. Epub ahead of print
34.
Zheng Z, Jiang L, Ye L, Gao Y, Tang L, Zhang M. The accuracy of presepsin for the diagnosis of sepsis from SIRS: a systematic review and meta-analysis. Ann Intern Med. 2015;5(1):48.
35.
Gilfillan M, Bhandari V. Biomarkers for the diagnosis of neonatal sepsis and necrotizing enterocolitis: clinical practice guidelines. Early Hum Dev. 2017;105:25–33.CrossRef
36.
Stocker M, van Herk W, El Helou S, et al. Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns). Lancet. 2017;390:871–81.CrossRef
37.
Sarkar S, Bhagat I, Wiswell TE, Spitzer AR. Role of multiple site blood cultures to document the clearance of bacteremia in neonates. J Perinatol. 2007;27:101–2.CrossRef
Metadata
Title
Soluble CD14 subtype (sCD14-ST) as biomarker in neonatal early-onset sepsis and late-onset sepsis: a systematic review and meta-analysis
Authors
Iris van Maldeghem
Charlotte M. Nusman
Douwe H. Visser
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Immunology / Issue 1/2019
Electronic ISSN: 1471-2172
DOI
https://doi.org/10.1186/s12865-019-0298-8

Other articles of this Issue 1/2019

BMC Immunology 1/2019 Go to the issue

Research article

NK cell predicts the severity of acute graft-versus-host disease in patients after allogeneic stem cell transplantation using antithymocyte globulin (ATG) in pretreatment scheme

Research article

Association of proinflammatory genes expression with serum interleukin 1β and free fatty acids in metabolically healthy and unhealthy abdominally obese individuals: a case-control study

Research article

Expression of ligands for activating natural killer cell receptors on cell lines commonly used to assess natural killer cell function

Research article

Low pre-transplant levels of mannose-binding lectin are associated with viral infections and mortality after haematopoietic allogeneic stem cell transplantation

Research article

Immunogenicity of Del19 EGFR mutations in Chinese patients affected by lung adenocarcinoma

Methodology article

Simple propagation method for resident macrophages by co-culture and subculture, and their isolation from various organs
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits